Optimal management of chronic heart failure in patients with chronic kidney disease

Journal of Renal Care

Volumn 35, Issue 1, 2009, Pages 2-10

  Zachariah, Donah ^a   Kalra, Philip A ^b   Kalra, Paul R ^a  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Atherosclerosis renovascular disease; Chronic kidney disease; Heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CHRONIC KIDNEY FAILURE; COMORBIDITY; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; COMORBIDITY; HEART FAILURE; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 61849105304     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2009.00069.x     Document Type: Article

References (43)

1. Bardy G.H., Lee K.L., Mark D.B. et al., for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine 352, 225-237.
2. Clark A.L. (2006). Origin of symptoms in chronic heart failure. Heart 92(1), 12-16.
3. Cleland J.G., Daubert J.C., Erdmann E. et al., for the Cardiac Resynchronization Heart Failure (CARE-HF) Study Investigators. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Mediclne 352, 1539-1549.
4. Cohn J.N. & Tognoni G., for the Valsartan Heart Failure Trial Investigators. (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 345, 1667-1675.
5. Cohn J.N., Johnson G., Ziesche S. et al. (1991). A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine 325, 303-310.
6. Cohn J.N., Tam S.W., Anand I.S. et al., for the A-HeFT Investigators. (2007). Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failurei results from A-HeFT. Journal of Cardiac Failure 13(5), 331-339.
7. Cooper C.J., Murphy T.P., Matsumoto A. et al. (2006). Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. American Heart Journal 152(1), 59-66.
8. Costanzo M.R. (2008). Ultra filtration in the management of heart failure. Current Opinion in Critical Care 14(5), 524-530.
9. Cowburn P.J., Patel H., Jolliffe R.E. et al. (2005). Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure? European Journal of Heart Failure 7(2), 215-217.
10. Cowie M.R., Komajda M., Murray Thomas T. et al. for the POSH Investigators. (2006). Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). European Heart Journal 27(10), 1216-1222.
11. Damman K., Navis G., Smilde T.D. et al. (2007a). Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. European Journal of Heart Failure 9(9), 872-878.
12. Damman K., Navis G., Voors A.A. et al. (2007b). Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. Journal of Cardiac Failure 13(8), 599-608.
13. de Mattos A.M., Siedlecki A., Gaston R.S. et al. (2008). Systolic dysfunction portends increased mortality among those waiting for renal transplant. Journal of the American Society of Nephrology 19(6), 1191-1196.
14. Digitalis Investigation Group. (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine 336(8), 525-533.
15. Erdmann E., Lechat P., Verkenne P. et al. (2001). Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. European Journal of Heart Failure 3(4), 469-479.
16. Foley R.N., Parfrey P.S., Harnett J.D. et al.. (1995). Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney International 47, 186-192.
17. Fox K.F., Cowie M.R., Wood D.A. et al. (2001). Coronary artery disease as the cause of incident heart failure in the population. European Heart Journal 22(3), 228-236.
18. Gheorghiade M., Orlandi C., Burnett J.C. et al. (2005) Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Cardiac Failure 11(4), 260-269.
19. Go A.S., Yang J., Ackerson L.M. et al. (2006) Haemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113(23), 2713-2723.
20. Hillege H.L., Nitsch D., Pfeffer M.A. et al. for the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. (2006). Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113(5), 671-678.
21. Hjalmarson A., Goldstein S., Fagerberg B. et al., for the MERIT-HF Study Group. (2000). Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). The Journal of the American Medical Association 283, 1295-1302.
22. Hobbs R.E., Tang W.H. (2006). Vasopressin receptor antagonists in heart failure. Recent Patents on Cardiovascular Drug Discovery 1(2), 177-184.
23. Hobson A., Kalra P.A., Kalra P.R. (2005). Cardiology and nephrology: time for a more integrated approach to patient care? European Heart Journal 26(16), 1576-1578.
24. Hou F.F., Zhang X., Zhang G.H. et al. (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. New England Journal of Medicine 354(2), 131-140.
25. Juurlink D.N., Mamdani M.M., Lee D.S. et al. (2004). Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine 351(6), 543-551.
26. Kalra P.A., Guo H., Kausz A.T. et al. (2005). Atherosclerotic renovascular disease in US medicare recipients aged 67 years or more: risk factors, revascularization and prognosis. Kidney International 68, 293-301.
27. Kalra P.R., Bolger A.P., Francis D.P. et al. (2003a). Effect of anemia on exercise tolerance in chronic heart failure in men. American Journal of Cardiology 91(7), 888-891.
28. Kalra P.R., Collier T., Cowie M.R. et al. (2003b). Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362(9379), 211-212.
29. Kalra P.R., Sharma R., Shamim W. et al. (2002). Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. International Journal of Cardiology 86(2-3), 225-231.
30. Levey A.S., Beto J.A., Coronado B.E. et al. (1998). The epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. American Journal of Kidney Diseases 32, 853-906.
31. Levin A., Thompson C.R., Ethier J. et al. (1999). Left ventricular mass index in early renal disease. Impact of a decline in hemoglobin. American Journal of Kidney Diseases 34, 125-134.
32. Ljungman S., Kjekshus J., Swedberg K. (1992). Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). American Journal of Cardiology 70(4), 479-487.
33. McMurray J.J., Ostergren J., Swedberg K. et al., for the CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767-771.
34. Mistry S., Ives N., Harding J. et al. (2007) Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. Journal of Human Hypertension 21(7), 511-515.
35. Packer M., Bristow M.R., Cohn J.N. et al., for the U.S. Carvedilol Heart Failure Study Group. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine 334, 1349-1355.
36. Patrick S.P. & Robert N.F. (1999). The Clinical Epidemiology of Cardiac Disease in Chronic Renal Failure. Journal of the American Society of Nephrology 10, 1606-1615.
37. Pitt B., White H., Nicolau J. et al., for the EPHESUS Investigators. (2005). Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology 46(3), 425-431.
38. Pitt B., Zannad F., Remme W.J. et al., for the Randomized Aldactone Evaluation Study (RALES) Investigators. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine 341, 709-717.
39. Schrier R.W. & Abraham W.T. (1999). Hormones and hemodynamics in heart failure. New England Journal of Medicine 341(8), 577-585.
40. SOLVID Investigators. (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 325, 293-302.
41. Swedberg K., Cleland J., Dougie H. et al. for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005). Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European Heart Journal 26(11), 1115-1140.
42. Toblli J.E., Lombraña A., Duarte P. et al. (2007) Intravenous iron reduces NT-pro-brain natriuretic peptice in anemic patients with chronic heart failure and renal insufficiency. Journal of the American College of Cardiology 50(17), 1657-1665.
43. Wright J.R., Shurrab A.E., Cooper A. et al. (2005). Left ventricular morphology and function in patients with atherosclerotic renovascular disease. Journal of the American Society of Nephrology 16(9), 2746-2753.